Northwestern Mutual Wealth Management Co. Acquires 795 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Northwestern Mutual Wealth Management Co. raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 8.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,252 shares of the medical research company’s stock after acquiring an additional 795 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in IQVIA were worth $2,168,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of IQV. Goldman Sachs Group Inc. grew its stake in shares of IQVIA by 21.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 837,865 shares of the medical research company’s stock worth $193,865,000 after purchasing an additional 148,568 shares during the period. Cibc World Markets Corp raised its position in shares of IQVIA by 133.3% in the 4th quarter. Cibc World Markets Corp now owns 23,577 shares of the medical research company’s stock valued at $5,455,000 after acquiring an additional 13,470 shares during the period. Pinebridge Investments L.P. boosted its stake in IQVIA by 31.0% during the 4th quarter. Pinebridge Investments L.P. now owns 15,366 shares of the medical research company’s stock worth $3,555,000 after acquiring an additional 3,639 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in IQVIA by 3.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 503,431 shares of the medical research company’s stock worth $116,484,000 after acquiring an additional 14,875 shares during the last quarter. Finally, Prudential PLC grew its holdings in IQVIA by 226.4% during the fourth quarter. Prudential PLC now owns 20,594 shares of the medical research company’s stock valued at $4,765,000 after purchasing an additional 14,284 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 1.1 %

NYSE:IQV opened at $229.84 on Friday. The firm has a market capitalization of $41.88 billion, a price-to-earnings ratio of 31.40, a price-to-earnings-growth ratio of 2.21 and a beta of 1.49. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The stock’s 50 day moving average price is $240.74 and its two-hundred day moving average price is $232.70.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same period in the prior year, the firm posted $2.22 earnings per share. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. Equities research analysts expect that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on IQV. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and lowered their price target for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. Barclays lifted their price objective on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Truist Financial increased their target price on IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Finally, UBS Group lifted their price target on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.00.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.